New drug targets 'Undruggable' cancer mutation in early trial
Disease control
Recruiting now
This early-phase study tests a new drug, CLSP-1025, designed to attack cancer cells that have a specific change in the p53 gene (called R175H). The study enrolls adults with advanced solid tumors (like lung, colon, or breast cancer) that have this mutation and a specific immune t…
Phase: PHASE1 • Sponsor: Clasp Therapeutics, Inc. • Aim: Disease control
Last updated Jun 17, 2026 00:15 UTC